ClinicalTrials.gg

Program

SRSD107

A development code.

Its studies are mostly in Thrombosis · Coronary Artery Disease · Venous Thromboembolism, led by Sirius Therapeutics.

Furthest: phase 2, since Aug 11, 20254 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sirius Therapeutics42 open or runningphase 2since Aug 11, 2025Oct 30, 2023Dec 2027phase 2 · NCT07318155

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 30, 2023First study: phase 1 study in ThrombosisFirst studyNCT06116617 · 40 enrolled · Australia
  2. Aug 11, 2025Phase 2 study in Venous ThromboembolismNCT07140523 · 450 planned · Czechia
  3. Dec 7, 2025Phase 2 study in Coronary Artery DiseaseNCT07318155 · 104 planned · China
  4. Jun 8, 2026Phase 1 study in ThrombosisNCT07655427 · 48 enrolled · China

Ahead

  1. Dec 2027Primary completion: phase 2 study in Coronary Artery DiseaseNCT07318155

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07655427Thrombosis · China1CompletedMar 2, 202548
NCT07318155Coronary Artery Disease · China2RecruitingDec 2027104
NCT07140523Venous Thromboembolism · Czechia2RecruitingJun 30, 2026450
NCT06116617Thrombosis · Australia1CompletedDec 9, 202440

How it is read

Names in the registry

  • “SRSD107”, 4 entries

Codes read as this program: SRSD107.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.